Envisia Therapeutics Inc. is using its PRINT microparticle formulation technology to develop sustained-release, implantable versions of approved drugs for glaucoma and age-related macular edema. The products could solve compliance problems with existing therapeutics and could deliver drugs for a longer period than similar products in development.

Envisia spun out of Liquidia Technologies Inc. last year with rights to use the PRINT (particle replication in non-wetting templates) platform for ophthalmic indications. PRINT is a templated nanofabrication method for producing microparticles and nanoparticles with highly specific and consistent shape, size and chemical composition.